Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) SVP Paula Green sold 1,347 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $64,656.00. Following the completion of the sale, the senior vice president now directly owns 114,147 shares of the company’s stock, valued at approximately $5,479,056. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Paula Green also recently made the following trade(s):
- On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total value of $246,147.40.
- On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $43,928.92.
- On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total value of $143,025.10.
- On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The shares were sold at an average price of $46.94, for a total transaction of $13,941.18.
Twist Bioscience Stock Down 6.1 %
TWST traded down $2.77 during trading hours on Wednesday, hitting $42.49. The company’s stock had a trading volume of 962,106 shares, compared to its average volume of 941,048. Twist Bioscience Co. has a fifty-two week low of $18.59 and a fifty-two week high of $60.90. The company has a 50-day simple moving average of $43.86 and a 200 day simple moving average of $45.95.
Institutional Investors Weigh In On Twist Bioscience
Analysts Set New Price Targets
Several research firms have recently commented on TWST. Barclays decreased their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Evercore ISI lifted their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners upped their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Robert W. Baird raised their price target on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $51.22.
Read Our Latest Analysis on Twist Bioscience
About Twist Bioscience
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Read More
- Five stocks we like better than Twist Bioscience
- Golden Cross Stocks: Pattern, Examples and Charts
- Rocket Lab is the Right Stock for the Right Time
- Quiet Period Expirations Explained
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- What is a Low P/E Ratio and What Does it Tell Investors?
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.